SG Americas Securities’s China Biologic Products Holdings, Inc. CBPO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-1,690
| Closed | -$200K | – | 3443 |
|
|
2021
Q1 | $200K | Sell |
1,690
-860
| -34% | -$102K | ﹤0.01% | 2682 |
|
|
2020
Q4 | $301K | Buy |
2,550
+1,316
| +107% | +$153K | ﹤0.01% | 2360 |
|
|
2020
Q3 | $137K | Buy |
1,234
+255
| +26% | +$27.4K | ﹤0.01% | 2330 |
|
|
2020
Q2 | $100K | Sell |
979
-45
| -4% | -$4.82K | ﹤0.01% | 3383 |
|
|
2020
Q1 | $111K | Sell |
1,024
-536
| -34% | -$61.6K | ﹤0.01% | 2924 |
|
|
2019
Q4 | $182K | Buy |
1,560
+50
| +3% | +$5.79K | ﹤0.01% | 2550 |
|
|
2019
Q3 | $173K | Sell |
1,510
-455
| -23% | -$45.2K | ﹤0.01% | 2428 |
|
|
2019
Q2 | $187K | Buy |
+1,965
| New | +$185K | ﹤0.01% | 2454 |
|
|
2018
Q1 | – | Sell |
-1,482
| Closed | -$117K | – | 3764 |
|
|
2017
Q4 | $117K | Buy |
+1,482
| New | +$123K | ﹤0.01% | 2777 |
|
|
2017
Q3 | – | Sell |
-17,414
| Closed | -$1.97M | – | 3908 |
|
|
2017
Q2 | $1.97M | Buy |
17,414
+4,028
| +30% | +$450K | 0.02% | 903 |
|
|
2017
Q1 | $1.34M | Sell |
13,386
-2,741
| -17% | -$293K | 0.01% | 1166 |
|
|
2016
Q4 | $1.73M | Buy |
16,127
+10,129
| +169% | +$1.18M | 0.01% | 974 |
|
|
2016
Q3 | $747K | Buy |
+5,998
| New | +$708K | 0.01% | 1392 |
|
SG Americas Securities's CBPO Position: Q2 2021 in Review
SG Americas Securities sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2021, closing a stake of 1,690 shares — an estimated $200K sold.
SG Americas Securities first reported a position in CBPO in Q3 2016 and held it in 13 quarters. The position peaked at $1.97M in Q2 2017. 0 funds tracked by Wall St. Rank hold CBPO as of Q2 2021.
- SG Americas Securities reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2021 after selling out during the quarter.
- SG Americas Securities sold 1,690 China Biologic Products Holdings, Inc. shares in Q2 2021, an estimated $200K.
- SG Americas Securities first reported a position in China Biologic Products Holdings, Inc. in Q3 2016 and held it in 13 quarters.
- SG Americas Securities's China Biologic Products Holdings, Inc. position peaked at $1.97M in Q2 2017.
- 0 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2021.
Based on SG Americas Securities's 13F filing for Q2 2021, filed 12 Aug 2021.